Neutrophil Extracellular Traps in Hematologic Disorders

Abstract

Neutrophil extracellular traps (NETs) are web-like structures composed of DNA, histones, and antimicrobial proteins released by neutrophils in response to various stimuli. In recent years, NETs have been implicated in the pathogenesis and clinical course of numerous hematologic disorders, including thrombosis, malignancy, and autoimmune cytopenias. This review provides a comprehensive analysis of the current understanding of NETs in hematologic diseases, highlighting epidemiological trends, mechanistic insights, diagnostic considerations, and advances in management. Recent evidence underscores the dual role of NETs in both host defense and disease exacerbation, with novel therapeutic strategies on the horizon targeting NETosis pathways. Clinicians must be aware of NET's contributions to disease burden and consider their implications for diagnosis and treatment in hematologic practice.

Introduction

Neutrophil extracellular traps (NETs) represent a specialized form of innate immune response wherein neutrophils expel nuclear material combined with granular proteins to immobilize and neutralize pathogens. While NETs play a crucial role in the containment of infectious agents, increasing evidence suggests that dysregulated NET formation, or NETosis, contributes to the development and progression of various hematologic disorders. The interplay between NETs and the hemostatic, inflammatory, and immune systems has profound implications for understanding disease mechanisms and for therapeutic innovation. This review synthesizes current knowledge on NETs in the context of hematologic diseases, emphasizing clinical and research advancements relevant to healthcare professionals.

Epidemiology / Disease Burden

The clinical significance of NETs in hematologic disorders is increasingly recognized, with studies reporting elevated NET markers in conditions such as venous thromboembolism (VTE), sickle cell disease, and hematologic malignancies. The prevalence of NET-related complications varies across disorders; for instance, approximately 30–40% of patients with cancer-associated thrombosis exhibit increased circulating NETs. In autoimmune cytopenias, such as immune thrombocytopenia (ITP), NETs have been detected in both pediatric and adult patients, correlating with disease severity. Global epidemiological data remain limited, but emerging multi-center studies are beginning to elucidate the burden of NET-driven pathology in hematology.

Pathophysiology

NETosis is triggered by diverse stimuli, including pathogens, immune complexes, pro-inflammatory cytokines, and activated platelets. The process involves chromatin decondensation, disintegration of nuclear and granular membranes, and release of chromatin decorated with neutrophil elastase, myeloperoxidase, and antimicrobial peptides. In hematologic disorders, excessive or aberrant NETosis can drive thrombogenesis by providing a scaffold for platelet adhesion and coagulation factor activation. In malignant settings, tumor-derived factors can induce NET formation, which in turn promotes tumor growth, metastasis, and immune evasion. In autoimmune cytopenias, NETs may expose autoantigens and perpetuate immune dysregulation. The pathophysiological relevance of NETs extends to the microenvironment, influencing endothelial integrity and local immune responses.

Risk Factors

Several factors predispose individuals to excessive NET formation in hematologic disorders. These include genetic polymorphisms affecting neutrophil function, chronic inflammation, infection, malignancy, and exposure to certain drugs (e.g., granulocyte colony-stimulating factor). Patients with inherited neutrophil defects or chronic granulomatous disease may exhibit abnormal NETosis. Comorbidities such as diabetes and cardiovascular disease further amplify NET-related risk, particularly in the context of prothrombotic states. Disease-specific factors, such as the presence of JAK2 V617F mutations in myeloproliferative neoplasms, have also been linked to enhanced NETosis and associated complications.

Clinical Features

Clinically, NET-mediated pathology manifests as thrombosis, organ dysfunction, and exacerbation of primary hematologic disease. In VTE and pulmonary embolism, NETs are detected in thrombi and peripheral blood, correlating with clot burden and recurrent events. In sickle cell disease, NETs contribute to vaso-occlusive crises and acute chest syndrome. Hematologic malignancies, particularly acute myeloid leukemia and myeloproliferative disorders, display increased NET formation, which may predict poor outcomes and risk of leukostasis. In cytopenias, NET-driven immune activation can result in refractory or relapsing disease courses. NETs may also contribute to microangiopathy and secondary organ damage in these conditions.

Diagnosis

Quantification of NETs in clinical practice remains challenging. Laboratory markers include circulating cell-free DNA, histone-DNA complexes, and neutrophil elastase–DNA complexes, typically measured by ELISA or immunofluorescence techniques. Flow cytometry and imaging-based assays allow for direct visualization and quantification of NETs in blood and tissue samples. However, standardization of diagnostic criteria is lacking, and interpretation requires correlation with clinical context. Biomarker-guided diagnosis is evolving, with efforts focused on identifying specific NET components associated with disease activity and prognosis in hematologic patients.

Treatment & Management

Therapeutic strategies targeting NETs in hematologic disorders are under active investigation. Anticoagulants, such as heparin, possess NET-inhibitory properties and remain mainstays for thrombotic complications. DNase enzymes, which degrade extracellular DNA, have shown promise in preclinical models by reducing NET-mediated thrombosis and inflammation. Immunomodulatory agents, including corticosteroids and intravenous immunoglobulin, may indirectly suppress NETosis in autoimmune cytopenias. In malignancy, targeting upstream NETosis mediators such as PAD4 and neutrophil elastase is a novel approach under clinical evaluation. Multidisciplinary management, encompassing hematologists, immunologists, and vascular specialists, is critical for optimizing outcomes in NET-driven disease.

Recent Advances / Emerging Therapies

Recent advances have elucidated the role of peptidylarginine deiminase 4 (PAD4) inhibitors and recombinant DNase as targeted therapies for NET-mediated pathology. Clinical trials are underway to assess the efficacy of these agents in reducing thrombosis and organ injury in patients with myeloproliferative neoplasms and sickle cell disease. Monoclonal antibodies against NET components, such as citrullinated histones, offer another therapeutic avenue. Innovative diagnostic platforms leveraging next-generation sequencing and multiplex immunoassays are enhancing our ability to monitor NET dynamics in vivo. These developments hold significant promise for personalized medicine approaches in hematology.

Guideline Recommendations

Current international guidelines, including those from the American Society of Hematology and the International Society on Thrombosis and Haemostasis, recognize the emerging role of NETs in hematologic disorders but stop short of recommending routine clinical testing or targeted therapy outside research settings. Consensus panels emphasize the importance of thromboprophylaxis in high-risk patients and suggest consideration of NET-modulating agents in refractory cases within clinical trials. Ongoing guideline updates are anticipated as evidence from interventional studies matures.

Conclusion

Neutrophil extracellular traps represent a pivotal mechanism linking innate immunity to the pathogenesis of diverse hematologic disorders. Their role in promoting thrombosis, inflammation, and immune dysregulation is increasingly recognized, with significant clinical implications for diagnosis, risk stratification, and therapeutic intervention. Ongoing research and emerging therapies targeting NET formation and function offer hope for improved patient outcomes. Continued multidisciplinary collaboration and translational research are essential to fully harness the potential of NET-directed strategies in hematologic practice.